Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Washington University School of Medicine
Study ID
NCT00548418
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Topotecan — DRUG
  • Cisplatin — DRUG
  • Bevacizumab — DRUG

Study Details

The purpose of this study is to determine whether the combination of topotecan, cisplatin and bevacizumab is effective in the treatment of recurrent or persistent cervical cancer

Key Dates

First listed
Oct 24, 2007
Start date
Feb 28, 2007
Status verified
Jul 2014
Primary completion
Dec 31, 2012
Completion
Dec 31, 2012

Study Design

Enrollment
27 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: I
    Cisplatin 50 mg/m2 IV day 1 of a 21 day cycle Topotecan 0.75 mg/m2 IV Days 1, 2, 3 of a 21 day cycle Bevacizumab 15 mg/kg day 1 of a 21 day cycle

Primary Outcome Measure

Anti-tumor Activity as Measured by Surviving Progression-free [ Time Frame: Progression-free survival at 6 months ]

Locations (3)

FacilityCityStateZIPSite coordinators
Washington University School of MedicineSt LouisMissouri63110-
Duke Cancer InstituteDurhamNorth Carolina--
The Ohio State University College of MedicineColumbusOhio--

Find similar trials in St Louis, MO

By condition
Cervical cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Washington University School of Medicine· St Louis, MODuke Cancer Institute· Durham, NCThe Ohio State University College of Medicine· Columbus, OH

Related Studies